Regeneron Pharmaceuticals REGN
- Market cap
- $100B
- PE
- 24.0×
- 10y median 19.7×
- Forward PE
- 15.1×
- 10y median 17.3×
- Price to sales
- 6.4×
- EV/EBIT
- 18.8×
- Revenue, 12 months
- $15.5B
- +9% on a year ago
- Net margin
- 27.9%
- Free cash flow yield
- 3.8%
Regeneron Pharmaceuticals trades at 24.0× trailing earnings, pricier than 65% of the last ten years. Revenue was $15.5B over the last twelve months, up 9% on a year earlier with a 28% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.4B+15% | $3.4B+1% | $3.1B−1% | $3.5B+12% | $3.7B+11% | $3.8B+10% | $3B−4% | $3.7B+4% | $3.8B+1% | $3.9B+3% | $3.6B+19% | $4.3B+17% | |
| Cost of revenue | $436.4M+37% | $517M−4% | $433.8M−5% | $480.2M+19% | $491.1M+13% | $565.4M+9% | $464.3M+7% | $530.2M+10% | $521.6M+6% | $584.6M+3% | $669.4M+44% | $576.5M+9% |
| Gross profit | $2.9B+12% | $2.9B+2% | $2.7B+0% | $3.1B+11% | $3.2B+10% | $3.2B+11% | $2.6B−5% | $3.1B+3% | $3.2B+0% | $3.3B+2% | $2.9B+15% | $3.7B+18% |
| R&D | $1.1B+18% | $1.2B+13% | $1.2B+13% | $1.2B+11% | $1.3B+18% | $1.4B+20% | $1.3B+6% | $1.4B+19% | $1.5B+16% | $1.6B+15% | $1.5B+16% | $1.6B+15% |
| SG&A | $640.5M+21% | $737.7M+12% | $689M+15% | $758.8M+16% | $714.4M+12% | $792.2M+7% | $633M−8% | $634.2M−16% | $657.8M−8% | $775M−2% | $647.7M+2% | $662.1M+4% |
| $1.1B−9% | $972.9M−15% | $751.4M−21% | $1.1B+5% | $1.2B+6% | $990.2M+2% | $591.7M−21% | $1.1B+1% | $1B−13% | $879.9M−11% | $642.9M+9% | $1.3B+20% | |
| Interest expense | $17.8M+16% | $18.3M+5% | $16.1M−11% | $14.8M−22% | $13.8M−23% | $10.5M−43% | $8.7M−46% | $3.6M−76% | $19.3M+40% | $12.2M+16% | $12.9M+48% | $11M+206% |
| Pre-tax income | $1.1B−26% | $1.1B−13% | $700.7M−18% | $1.6B+50% | $1.5B+34% | $958.1M−17% | $905M+29% | $1.5B−7% | $1.8B+18% | $1B+9% | $831.2M−8% | $1.5B+1% |
| $103M−47% | −$12M | −$21.3M | $195.8M+71% | $152.4M+48% | $40.4M | $96.3M | $127.1M−35% | $303.3M+99% | $199.1M+393% | $104M+8% | $230.9M+82% | |
| Net income | $1B−23% | $1.2B−3% | $722M−12% | $1.4B+48% | $1.3B+33% | $917.7M−21% | $808.7M+12% | $1.4B−3% | $1.5B+9% | $844.6M−8% | $727.2M−10% | $1.3B−7% |
| $8.89−24% | $10.20−3% | $6.27−13% | $12.41+46% | $11.54+30% | $8.08−21% | $7.27+16% | $12.81+3% | $13.62+18% | $7.84−3% | $6.75−7% | $12.23−5% | |
| 113.4M+1% | 113.7M−0% | 115.1M+1% | 115.4M+1% | 116.2M+3% | 113.6M−0% | 111.2M−3% | 108.6M−6% | 107.2M−8% | 107.7M−5% | 107.7M−3% | 106M−2% |
Gross profit: 69 periods, Q2 FY09 to Q2 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 13 periods, Q2 FY09 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 3 periods, Q4 FY09 to Q4 FY11: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 14 periods, Q4 FY12 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $4.6B | $4.4B to $4.7B | $16.51 | $15.60 to $17.62 | 15 |
| Q4 FY26 | $5.8B | $5B to $6.5B | $24.48 | $18.60 to $31.78 | 14 |
| Q1 FY27 | $4.6B | $4.5B to $4.7B | $15.95 | $13.94 to $17.39 | 6 |
| Q2 FY27 | $5.1B | $4.5B to $5.6B | $19.08 | $16.22 to $21.08 | 2 |
| Q3 FY27 | $5.3B | $4.7B to $5.7B | $19.39 | $16.49 to $21.43 | 2 |
| Q4 FY27 | $5.6B | $4.9B to $6B | $20.81 | $17.69 to $23.00 | 2 |
| Q1 FY28 | $4.9B | $4.3B to $5.3B | $17.86 | $15.19 to $19.74 | 5 |
| Q2 FY28 | $5.4B | $4.8B to $5.9B | $20.84 | $17.71 to $23.02 | 5 |
Peers
Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| REGNRegeneron Pharmaceuticals | $100B | 24.0× | 19.7× | 15.1× | 6.4× | +9% | 27.9% |
| VRTXVertex Pharmaceuticals | $137.1B | 31.5× | 28.6× | 27.9× | 10.9× | +10% | 35.0% |
| ONCBeOne Medicines | $40.2B | 63.2× | 67.6× | 45.0× | 6.6× | +34% | 10.7% |
| UTHRUnited Therapeutics | $25.9B | 21.6× | 14.2× | 22.6× | 8.2× | +2% | 41.6% |
| INCYIncyte | $24.3B | 15.3× | 36.5× | 51.3× | 4.2× | +27% | 27.7% |
| ALNYAlnylam Pharmaceuticals | $21.2B | 26.7× | 68.2× | 18.9× | 4.4× | +95% | 16.8% |
| EXELExelixis | $17.4B | 22.1× | 22.7× | n/m | 7.1× | +9% | 35.3% |
| NBIXNeurocrine Biosciences | $14.8B | 21.3× | 42.6× | n/m | 4.4× | +34% | 20.9% |
| HALOHalozyme Therapeutics | $14.6B | 38.5× | 21.3× | n/m | 8.8× | +41% | 24.9% |
| TECHBIO-TECHNE | $11.4B | 63.2× | 62.0× | n/m | 9.4× | −0% | 15.0% |
| Peer median | $21.2B | 26.7× | 36.5× | 27.9× | 7.1× | +27% | 24.9% |
More on Regeneron Pharmaceuticals
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 34Healthcare stocks with the lowest PEG ratio
- #6of 53Healthcare stocks with the fastest expected revenue growth
- #7of 29Biotech stocks with the highest profit margins
- #8of 17Biotech stocks with the highest free cash flow yield
- #8of 16Biotech stocks with the lowest PE ratio
- #9of 17Biotech stocks with the lowest EV/EBIT
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .